Repligen (RGEN) — insider trading
Health Care · NASDAQ
Repligen (RGEN) has 46 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 46 (latest 2026-10-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Douglass Brian Robb | Officer (CHIEF PRODUCT OFFICER) | Grant / award / vesting (derivative) | 675 | — | $0 | Form 4 |
| 2026-10-06 | Douglass Brian Robb | Officer (CHIEF PRODUCT OFFICER) | Grant / award / vesting | 700 | — | $0 | Form 4 |
| 2026-10-05 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 4,202 | — | $0 | Form 4 |
| 2026-10-05 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 4,202 | $190.00 | $798.4K | Form 4 |
| 2026-10-05 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 4,202 | $154.96 | $651.1K | Form 4 |
| 2026-10-05 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 1,333 | $178.75 | $238.3K | Form 4 |
| 2026-10-02 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 1,248 | $181.70 | $226.8K | Form 4 |
| 2026-09-25 | Garland Jason K | Officer (CFO) | Shares withheld for taxes / exercise cost | 421 | $189.68 | $79.9K | Form 4 |
| 2026-09-24 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 4,542 | — | $0 | Form 4 |
| 2026-09-24 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 8,404 | — | $0 | Form 4 |
| 2026-09-24 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 4,542 | $190.00 | $863.0K | Form 4 |
| 2026-09-24 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 4,542 | $155.38 | $705.7K | Form 4 |
| 2026-09-24 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 8,404 | $190.00 | $1.60M | Form 4 |
| 2026-09-24 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 8,404 | $154.96 | $1.30M | Form 4 |
| 2026-09-21 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 5,426 | — | $0 | Form 4 |
| 2026-09-21 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 5,426 | $180.00 | $976.7K | Form 4 |
| 2026-09-21 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 5,426 | $141.79 | $769.4K | Form 4 |
| 2026-09-04 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 3,035 | $165.90 | $503.5K | Form 4 |
| 2026-09-03 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 2,842 | $169.61 | $482.0K | Form 4 |
| 2026-09-01 | Hughes Violetta | Officer (CHIEF ACCOUNTING OFFICER) | Shares withheld for taxes / exercise cost | 277 | $170.02 | $47.1K | Form 4 |
| 2026-08-20 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 5,426 | — | $0 | Form 4 |
| 2026-08-20 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 5,426 | $180.00 | $976.7K | Form 4 |
| 2026-08-20 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 5,426 | $141.79 | $769.4K | Form 4 |
| 2026-07-16 | Garland Jason K | Officer (CFO) | Open-market sale | 530 | $150.00 | $79.5K | Form 4 |
| 2026-06-25 | Garland Jason K | Officer (CFO) | Open-market sale | 733 | $145.00 | $106.3K | Form 4 |
| 2026-05-14 | BARTHELEMY NICOLAS | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | BARTHELEMY NICOLAS | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-14 | DAWES KAREN A | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | DAWES KAREN A | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-14 | MUIR GLENN P | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | MUIR GLENN P | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-14 | Pax Margaret | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | Pax Margaret | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-14 | Mhatre Rohin | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | Mhatre Rohin | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-14 | EGLINTON MANNER CARRIE | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | EGLINTON MANNER CARRIE | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-14 | Konstantinov Konstantin | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | Konstantinov Konstantin | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-14 | Madaus Martin D | Director | Grant / award / vesting (derivative) | 2,239 | — | $0 | Form 4 |
| 2026-05-14 | Madaus Martin D | Director | Grant / award / vesting | 995 | — | $0 | Form 4 |
| 2026-05-07 | Douglass Brian Robb | Officer (CHIEF PRODUCT OFFICER) | Shares withheld for taxes / exercise cost | 334 | $126.43 | $42.2K | Form 4 |
| 2026-05-07 | MUIR GLENN P | Director | Option exercise / conversion (derivative) | 2,434 | — | $0 | Form 4 |
| 2026-05-07 | MUIR GLENN P | Director | Option exercise / conversion | 2,434 | $38.76 | $94.3K | Form 4 |
| 2026-04-21 | Loeillot Olivier | Director, Officer (Chief Executive Officer) | Open-market sale | 3,832 | $140.00 | $536.5K | Form 4 |
| 2026-03-05 | Hughes Violetta | Officer (CHIEF ACCOUNTING OFFICER) | Grant / award / vesting | 2,466 | — | $0 | Form 4 |
Ask the chat about RGEN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Repligen (RGEN).
Last updated 2026-10-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.